Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Indications and diagnostic yield of small-bowel capsule endoscopy in a real-world setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Liver Forum Standard of Care Working Group
Vis graf over relationer

Lifestyle modification is the foundation of treatment recommendations for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The design of clinical trials in NASH may be impeded by the lack of a systematic approach to identify and evaluate how lifestyle changes and/or modifications influence clinical trial outcomes and associated endpoints. Furthermore, there are additional uncertainties regarding the methods that can be utilised to better characterise and quantify lifestyle variables - which can influence disease activity and alter trial endpoints - to allow for comparisons of trial outcomes across different phases of research and/or within drug-classes. This summary by the Liver Forum's Standard of Care Working Group reviews currently available clinical data, identifies the barriers and challenges associated with the standard of care in NAFLD/NASH clinical trials, defines available assessments of lifestyle changes, and proposes approaches to better understand and define the influence of diet and exercise on NASH treatment in the context of different pharmacologic interventions. The ultimate objective is to propose tangible solutions which enable investigators, sponsors, and regulatory authorities to meaningfully interpret clinical trial outcomes and the impact of lifestyle modification on such outcomes as they pertain to phase I-IV clinical trials.

OriginalsprogEngelsk
TidsskriftJournal of Hepatology
Vol/bind73
Udgave nummer3
Sider (fra-til)680-693
Antal sider14
ISSN0168-8278
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

Copyright © 2020. Published by Elsevier B.V.

ID: 61702979